Chapters

Transcript

Video

SABCS 2022: Paolo Tarantino, MD

ATEMPT study shows that 5 years after treatment, 97% of patient's w/stage 1 HER2+ breast cancer treated w/TDM1 were alive and free from invasive disease and 98.3% had no recurrence of their cancer.


Published

December 19, 2022

Created by

Dana-Farber